Genome Mining and Drug Discovery of Marine Halophilic Microorganisms

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2519

Special Issue Editor


E-Mail Website
Guest Editor
Microbiology and Parasitology, University of Sevilla, Sevilla, Spain
Interests: taxonomy; halophilic microorganism; metagenomic; biodiversity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Marine organisms, including bacteria, archaea, fungi, phytoplankton, and larger algae, as well as some invertebrates, are currently considered potentially promising sources of bioactive substances. Findings of new marine microorganisms show the existence of native strains that produce a variety of chemically and biologically interesting secondary metabolites for the development and production of new compounds of importance in the pharmaceutical, cosmetic, nutritional supplements, biomolecules, biocatalysts, agrochemicals, chemical industries. fine, among others. Research on new metabolites of marine origin has increased considerably in the last times. Of all these secondary metabolites, antibiotics take on relevant importance due to the problems of bacterial resistance that threaten public health.

On the other hand, recent advances in DNA sequencing have led to an enormous increase in published procaryotes genomes and bioinformatics tools to analyze natural product biosynthetic potential by various “genome mining” approaches.

The microorganisms that we can cultivate are much less than those that actually exist in their natural habitats, including, of course, marine environments, therefore the search for new microorganisms that can be cultivated in these environments is a great challenge, and if we add to this that many of these microorganisms are capable of producing secondary metabolites, they constitute a large field to discover

Antimicrobial resistance is one of the major health problems facing humanity. More and more superbugs capable of overcoming available antibiotics are being detected and, if resistance continues to grow at the current rate, some 10 million people a year will die from bacterial infections by 2050, at a global economic cost that will exceed the 100,000 million dollars.

In recent years, in order to face these great public health problems, various marine ecosystems have been explored, representing one of the favorite habitats in the search for new bioactive metabolites. The increasing appearance of antibiotic-resistant pathogens has generated the need to evaluate various natural compounds with antimicrobial activity as an alternative in the treatment of infectious and contagious diseases and, in this way, counteract some of these public and veterinary health problems.

This Special Issue invites academic and industry scientists to submit reviews and original research articles from both, the discovery of new marine bacteria that produce new compounds and genomics-driven studies on marine bacteria focus on natural product discovery and characterization.

Dr. Cristina Sánchez-Porro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • halophilic
  • microorganisms
  • compatible solutes
  • bioactive molecules
  • antibiotics
  • resistance
  • biodiversity
  • metagenomic
  • secondary metabolites

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2376 KiB  
Article
Bioassay-Guided Fractionation Leads to the Detection of Cholic Acid Generated by the Rare Thalassomonas sp.
by Fazlin Pheiffer, Yannik K.-H. Schneider, Espen Holst Hansen, Jeanette Hammer Andersen, Johan Isaksson, Tobias Busche, Christian Rückert, Jörn Kalinowski, Leonardo van Zyl and Marla Trindade
Mar. Drugs 2023, 21(1), 2; https://doi.org/10.3390/md21010002 - 20 Dec 2022
Cited by 1 | Viewed by 2256
Abstract
Bacterial symbionts of marine invertebrates are rich sources of novel, pharmaceutically relevant natural products that could become leads in combatting multidrug-resistant pathogens and treating disease. In this study, the bioactive potential of the marine invertebrate symbiont Thalassomonas actiniarum was investigated. Bioactivity screening of [...] Read more.
Bacterial symbionts of marine invertebrates are rich sources of novel, pharmaceutically relevant natural products that could become leads in combatting multidrug-resistant pathogens and treating disease. In this study, the bioactive potential of the marine invertebrate symbiont Thalassomonas actiniarum was investigated. Bioactivity screening of the strain revealed Gram-positive specific antibacterial activity as well as cytotoxic activity against a human melanoma cell line (A2058). The dereplication of the active fraction using HPLC-MS led to the isolation and structural elucidation of cholic acid and 3-oxo cholic acid. T. actiniarum is one of three type species belonging to the genus Thalassomonas. The ability to generate cholic acid was assessed for all three species using thin-layer chromatography and was confirmed by LC-MS. The re-sequencing of all three Thalassomonas type species using long-read Oxford Nanopore Technology (ONT) and Illumina data produced complete genomes, enabling the bioinformatic assessment of the ability of the strains to produce cholic acid. Although a complete biosynthetic pathway for cholic acid synthesis in this genus could not be determined based on sequence-based homology searches, the identification of putative penicillin or homoserine lactone acylases in all three species suggests a mechanism for the hydrolysis of conjugated bile acids present in the growth medium, resulting in the generation of cholic acid and 3-oxo cholic acid. With little known currently about the bioactivities of this genus, this study serves as the foundation for future investigations into their bioactive potential as well as the potential ecological role of bile acid transformation, sterol modification and quorum quenching by Thalassomonas sp. in the marine environment. Full article
(This article belongs to the Special Issue Genome Mining and Drug Discovery of Marine Halophilic Microorganisms)
Show Figures

Figure 1

Back to TopTop